Related Experiment Videos
[Statins in diabetic hyperlipidemia]
R Kirchmair1, W Sturm, H Gänzer
1Klinischen Abteilung für Allgemeine Innere Medizin, Universitätsklinik Innsbruck.
Insights
Statins effectively lower cholesterol, reducing coronary heart disease mortality in diabetic patients more than in non-diabetics. Lipid-lowering therapies are crucial for managing cardiovascular risk in diabetes.
Area of Science:
- Cardiology
- Diabetology
- Pharmacology
Background:
- Diabetic patients face elevated cardiovascular risk.
- Dyslipidemia in diabetics often includes high triglycerides and low HDL-cholesterol.
- Existing evidence supports statin use for coronary heart disease reduction.
Purpose of the Study:
- To summarize evidence on lipid-lowering therapies for cardiovascular risk reduction in diabetic patients.
- To highlight ongoing research into specific lipid-lowering strategies for diabetes.
- To define target LDL-cholesterol levels for diabetic individuals.
Main Methods:
- Review of placebo-controlled prospective multicenter trials.
- Analysis of subgroup data from diabetic patients.
- Inclusion of ongoing studies evaluating fibrates and newer statins.
Main Results:
- Statins significantly reduce coronary heart disease mortality in diabetics.
- Lipid lowering also shows a trend towards stroke reduction in diabetic subgroups.
- Target LDL-cholesterol levels should not exceed 100 mg/dl for diabetic patients.
Conclusions:
- Lipid-lowering therapy, particularly with statins, is effective in reducing cardiovascular mortality in diabetic patients.
- Further research is investigating targeted therapies for diabetic dyslipidemia.
- Aggressive LDL-cholesterol control is recommended for primary and secondary prevention in diabetes.
Abstract:
Several placebo-controlled prospective multicenter trials showed convincing evidence that cholesterol lowering with statins reduced mortality due to coronary heart disease. Subgroup analyses of diabetic patients demonstrated significant reduction of coronary death rates in diabetics even more pronounced than that observed with the nondiabetic population. In some studies significant reduction of strokes was also achieved by lipid lowering. In one diabetic subgroup stroke reduction nearly reached significance despite low number of patients. New studies are currently in progress investigating the effect of lipid lowering specifically for diabetic patients. Some of these studies are designed to evaluate the effects of drugs acting primarily on triglycerides, such as the fibrates, or showing both, triglyceride and cholesterol reduction, like some newer statins, especially atorvastatin. The dyslipidemia encountered most frequently with diabetics is an increase of triglycerides and low HDL-cholesterol. Because of the high cardiovascular risk of diabetics the target levels of LDL-cholesterol in secondary and primary prevention should not exceed 100 mg/dl as in secondary prophylaxis in patients without diabetes.